Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cycurion, Inc.WAVS · Entity 6914 | Director | January 11, 2022 | January 11, 2022 |
| DarioHealth Corp.DRIO · Entity 7024 | Director | September 18, 2025 | September 28, 2026 |
| VivoSim Labs, INC.VIVS · Entity 8386 | Director | January 27, 2026 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cycurion, Inc.
Report date January 11, 2022 · Filed January 11, 2022
This filing explicitly reported no securities owned.
DarioHealth Corp.
Report date September 18, 2025 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy AKS Family Partners L.P. | 17,906 |
Reported balance
After 2025-09-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-09-18 · Conversion · Acquired 11,760 · Balance 17,906 F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. |
| Common StockSEC Table I · non-derivative | IndirectBy AKS Family Partners L.P. | 26,341 |
Reported balance
After 2025-09-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-09-18 · Conversion · Acquired 8,435 · Balance 26,341 F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 57,717 |
Reported balance
After 2026-09-24 transaction · row 3
1 source rowRow 3 · 2026-09-24 · Grant · Acquired 28,000 · Balance 57,717 F4: The restricted share award shall vest on the last day of the second-year anniversary after the grant date. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2025-09-18 | IndirectBy AKS Family Partners L.P. | 0 |
Reported balance
After 2025-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-09-18 · Conversion · Disposed 250 · Balance 0 F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. |
| Series D-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2025-09-18 | IndirectBy AKS Family Partners L.P. | 0 |
Reported balance
After 2025-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-18 · Conversion · Disposed 100 · Balance 0 F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations.
F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis.
F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock.
F4: The restricted share award shall vest on the last day of the second-year anniversary after the grant date.
VivoSim Labs, INC.
Report date January 27, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,899 |
Reported balance
After 2026-01-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 15,000 · Balance 19,899 F1: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. F2: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.
F2: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Matinas BioPharma Holdings, Inc.
Report date October 16, 2025 · Filed August 13, 2026
Section 16 reporting ended · disclosed 2026-08-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 113,450 |
Reported balance
After 2025-10-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-10-31 · Other · Acquired 92,100 · Balance 113,450 F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 743,785 |
Reported balance
After 2026-07-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-10 · Other · Acquired 630,335 · Balance 743,785 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough A.K.S Family Partners LP | 416,900 |
Reported balance
After 2026-07-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-10 · Other · Acquired 344,710 · Balance 416,900 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2030-04-08 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 800,000 |
Reported balance
After 2025-10-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-10-16 · Other · Acquired 800,000 · Balance 800,000 F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2030-04-08 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 630,335 |
Reported balance
After 2025-10-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-10-31 · Other · Disposed 92,100 · Balance 630,335 F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2030-04-08 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 0 |
Reported balance
After 2026-07-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-07-10 · Other · Disposed 630,335 · Balance 0 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 630,335 |
Reported balance
After 2026-07-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-07-10 · Grant · Acquired 630,335 · Balance 630,335 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 265 |
Reported balance
After 2025-10-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-10-16 · Other · Acquired 265 · Balance 265 F5: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date. F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2030-04-08 | IndirectThrough A.K.S Family Partners LP | 0 |
Reported balance
After 2026-07-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-07-10 · Other · Disposed 344,710 · Balance 0 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 | IndirectThrough A.K.S Family Partners LP | 344,710 |
Reported balance
After 2026-07-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-07-10 · Grant · Acquired 344,710 · Balance 344,710 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 | Direct | 141,462 |
Reported balance
After 2026-07-10 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-07-10 · Other · Acquired 141,462 · Balance 141,462 F3: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 28,260 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 28,260 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough AKS Family Foundation | 26,500 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 26,500 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough Pavillion Capital Partners LLC | 6,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 6,000 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough Piper Venture Partners LLC | 6,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 6,000 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough IRA Adam K Stern - Rollover IRA | 1,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,000 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough Stern Aegis Ventures LLC 401k Plan for the Benefit of Adam K Stern | 3,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 3,000 |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 | IndirectThrough AKS Family Partners | 101 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 101 F5: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date. F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.
F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.
F3: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern.
F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant.
F5: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-111351 · tm2626098-9_4seq1.xml · nonDerivative · entry 3 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,717 F4 · date: The restricted share award shall vest on the last day of the second-year anniversary after the grant date. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherWarrants to Purchase Common Stock · Derivative | 141,462 | $0.35 Strike: $0.35 | $49,511.70 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 17 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,462 Underlying: Common Stock, par value $0.0001 per share · 141,462 shares Expires not disclosed F3 · date: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern. F3 · derivative.exercise_date: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern. F3 · derivative.expiration_date: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantWarrants to Purchase Common Stock · Derivative | 344,710 | $0.35 Strike: $0.35 | $120,648.50 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 16 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through A.K.S Family Partners LP Disclosed balance after: 344,710 Underlying: Common Stock, par value $0.0001 per share · 344,710 shares Expires not disclosed F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F2 · derivative.exercise_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F2 · derivative.expiration_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F4 · ownership.nature: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherWarrants to Purchase Common Stock · Derivative | 344,710 | $0.35 Strike: $0.35 | $120,648.50 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 15 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through A.K.S Family Partners LP Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 344,710 shares Expires 2030-04-08 F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F4 · ownership.nature: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantWarrants to Purchase Common Stock · Derivative | 630,335 | $0.35 Strike: $0.35 | $220,617.25 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 14 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 630,335 Underlying: Common Stock, par value $0.0001 per share · 630,335 shares Expires not disclosed F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F2 · derivative.exercise_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F2 · derivative.expiration_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherWarrants to Purchase Common Stock · Derivative | 630,335 | $0.35 Strike: $0.35 | $220,617.25 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 13 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 630,335 shares Expires 2030-04-08 F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 630,335 | $0.35 | $220,617.25 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · nonDerivative · entry 3 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 743,785 F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F2 · price: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. Read SEC document |
| July 10, 2026 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 344,710 | $0.35 | $120,648.50 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · nonDerivative · entry 2 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through A.K.S Family Partners LP Disclosed balance after: 416,900 F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F2 · price: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 00:47 UTC | VivoSim Labs, INC. VIVS · Entity 8386 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-029875 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,899 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. F2 · balance_after: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. Read SEC document |
| October 31, 2025 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherWarrants to Purchase Common Stock · Derivative | 92,100 | $0.64 Strike: $0.64 | $59,367.66 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 12 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 630,335 Underlying: Common Stock, par value $0.0001 per share · 92,100 shares Expires 2030-04-08 F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. Read SEC document |
| October 31, 2025 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 92,100 | $0.64 | $59,367.66 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 113,450 F1 · date: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. F2 · price: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. Read SEC document |
| October 16, 2025 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherSeries C Convertible Preferred Stock · Derivative | 265 | $0.59 Strike: $0.59 | $155.29 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 11 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 265 Underlying: Common Stock, par value $0.0001 per share · 452,218 shares Expires not disclosed F5 · derivative.expiration_date: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date. F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. Read SEC document |
| October 16, 2025 Filed Aug 13, 2026 20:04 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherWarrants to Purchase Common Stock · Derivative | 800,000 | $0.64 Strike: $0.64 | $515,680.00 |
DisclosureSEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 10 STERN ADAM K · CIK 0001403497 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern Disclosed balance after: 800,000 Underlying: Common Stock, par value $0.0001 per share · 800,000 shares Expires 2030-04-08 F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. Read SEC document |
| September 18, 2025 Filed Sep 28, 2026 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionSeries D-2 Preferred Stock · Derivative | 100 | $1,000.00 Strike: $1,000.00 | $100,000.00 |
DisclosureSEC source: 0001104659-26-111351 · tm2626098-9_4seq1.xml · derivative · entry 5 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By AKS Family Partners L.P. Disclosed balance after: 0 Underlying: Common Stock · 8,435 shares Expires 2025-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.underlying_shares: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. Read SEC document |
| September 18, 2025 Filed Sep 28, 2026 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionSeries C Preferred Stock · Derivative | 250 | $1,000.00 Strike: $1,000.00 | $250,000.00 |
DisclosureSEC source: 0001104659-26-111351 · tm2626098-9_4seq1.xml · derivative · entry 4 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By AKS Family Partners L.P. Disclosed balance after: 0 Underlying: Common Stock · 11,760 shares Expires 2025-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.underlying_shares: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. Read SEC document |
| September 18, 2025 Filed Sep 28, 2026 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionCommon Stock | 8,435 | $16.60 | $140,021.00 |
DisclosureSEC source: 0001104659-26-111351 · tm2626098-9_4seq1.xml · nonDerivative · entry 2 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By AKS Family Partners L.P. Disclosed balance after: 26,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F3 · shares: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. F3 · price: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. Read SEC document |
| September 18, 2025 Filed Sep 28, 2026 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionCommon Stock | 11,760 | $40.40 | $475,104.00 |
DisclosureSEC source: 0001104659-26-111351 · tm2626098-9_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By AKS Family Partners L.P. Disclosed balance after: 17,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F2 · shares: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. F2 · price: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 22:03 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090097 · tm2526001-2_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,717 F1 · date: The restricted share award shall vest on the last day of the second-year anniversary after the grant date. F2 · balance_after: The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:04 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseSeries D-2 Preferred Stock · Derivative | 100 | $1,000.00 Strike: $0.83 | $100,000.00 |
DisclosureSEC source: 0001104659-25-002530 · tm252765-1_4seq1.xml · derivative · entry 4 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · AKS Family Partners L.P. Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_date: The Series D-2 Preferred Stock will automatically convert into shares of common stock, subject to shareholder approval and certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 12-month anniversary of the issuance date. The Series D-2 Preferred Stock initially converts into shares of common stock at a conversion price of $0.83. In addition, the holders of Series D-2 Preferred Stock will also be entitled dividends payable as follows: ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, all issuable upon conversion of the Preferred Stock. F1 · derivative.expiration_date: The Series D-2 Preferred Stock will automatically convert into shares of common stock, subject to shareholder approval and certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 12-month anniversary of the issuance date. The Series D-2 Preferred Stock initially converts into shares of common stock at a conversion price of $0.83. In addition, the holders of Series D-2 Preferred Stock will also be entitled dividends payable as follows: ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, all issuable upon conversion of the Preferred Stock. F1 · derivative.underlying_shares: The Series D-2 Preferred Stock will automatically convert into shares of common stock, subject to shareholder approval and certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 12-month anniversary of the issuance date. The Series D-2 Preferred Stock initially converts into shares of common stock at a conversion price of $0.83. In addition, the holders of Series D-2 Preferred Stock will also be entitled dividends payable as follows: ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, all issuable upon conversion of the Preferred Stock. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:01 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-094723 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,821 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:15 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-032397 · tm248350-1_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,341 F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period. Read SEC document |
| February 15, 2024 Filed Mar 1, 2024 21:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantSeries-C Preferred Stock · Derivative | 250 | $1,000.00 Strike: $2.02 | $250,000.00 |
DisclosureSEC source: 0001104659-24-029952 · tm247605-1_4seq1.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · AKS Family Partnership, L.P Disclosed balance after: 250 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_date: Subject to beneficial ownership limitations provided for in the offering documents relating to the sale of the Series-C Preferred Stock, each share of Series-C Preferred Stock shall automatically convert into shares of the registrant's common stock at the conversion price of $2.02 upon the earlier of (i) the 15-month anniversary of the effective date of the certificate of designation, or (ii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series-C Preferred. F1 · derivative.expiration_date: Subject to beneficial ownership limitations provided for in the offering documents relating to the sale of the Series-C Preferred Stock, each share of Series-C Preferred Stock shall automatically convert into shares of the registrant's common stock at the conversion price of $2.02 upon the earlier of (i) the 15-month anniversary of the effective date of the certificate of designation, or (ii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series-C Preferred. F2 · derivative.underlying_shares: The Series C Preferred Stock initially converts into shares of common stock at a conversion price of $2.02. In addition, the holders of Series c Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to seven and a half percent (7.5%) of the number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to fifteen percent (15%) of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock then held by such holder on the fifth full quarter from the closing date. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 23:43 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064956 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,214 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:12 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035798 · doc4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,607 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Read SEC document |
| May 18, 2022 Filed May 20, 2022 21:00 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-063443 · tm2216123-1_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,341 F1 · shares: The shares vest over three years as follows: 33.333% shall vest after 12 months from the grant date, and the remaining shares shall vest in 2 equal instalments every 2 years thereafter. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:00 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0000899243-21-039908 · doc4.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-10-07 F1 · derivative.exercise_date: The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:31 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-031483 · tm218474-1_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,341 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of March 2021. F1 · price: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of March 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:29 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-012964 · tm215402d1_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,772 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of February 2021. F1 · price: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of February 2021. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseRestricted Stock Grant | 43,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-006289 · tm213677-4_4seq1.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,103 F1 · date: The shares vest over three years as follows: 8.333% shall vest on March 31, 2021, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| January 19, 2021 Filed Mar 31, 2021 20:11 UTC Amendment | DarioHealth Corp. DRIO · Entity 7024 | PurchaseRestricted Stock Units | 43,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-044751 · tm2111379d3_4a.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,103 F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · date: The shares vest over three years as follows: one third of the shares vest on each annual anniversary date of the date of grant; provided, however that the shares shall vest on a pro rata basis on the date the Reporting Person's continuous service to the Issuer ceases. The shares shall immediately vest in the event of a change of control that occurs prior to, or within, 60 days of the termination of the Reporting Person's employment or retention with the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-001489 · tm211458d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,253 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of January 2021. F1 · price: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of January 2021. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-132410 · tm2037549d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,634 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of December 2020. F1 · price: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of December 2020. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-121339 · tm2034917d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,015 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of November 2020. F1 · price: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of November 2020. Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 502 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001104659-20-118931 · tm2034485d1_4.xml · derivative · entry 5 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502 Underlying: Common Stock · 502 shares Expires 2025-07-31 F1 · price: The reported securities were issued in the reporting person's name as a portion of the consideration provided to the placement agent (for whom the reporting person serves as Head of Private Equity Banking). Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 112,365 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001104659-20-118931 · tm2034485d1_4.xml · derivative · entry 4 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,365 Underlying: Common Stock · 112,365 shares Expires 2025-07-31 F1 · price: The reported securities were issued in the reporting person's name as a portion of the consideration provided to the placement agent (for whom the reporting person serves as Head of Private Equity Banking). Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-112181 · tm2032363d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,396 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of October 2020. F1 · price: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of October 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:27 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-20-051053 · doc4.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option shares vest and become exercisable over 12 equal quarterly installments measured from September 15, 2020. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 639 | $6.66 | $4,255.74 |
DisclosureSEC source: 0001104659-20-102624 · tm2030202d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,777 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of September 2020. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 14:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 20,000 | $0.83 | $16,600.00 |
DisclosureSEC source: 0001493152-20-016580 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,301,983 F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 24, 2020 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 639 | $6.66 | $4,255.74 |
DisclosureSEC source: 0001104659-20-097973 · tm2029295d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,138 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of August 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:11 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-085630 · tm2025176d9_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,499 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the second quarter of 2020. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 1,244 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 14 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,244 Underlying: Common Stock · 1,244 shares Expires 2024-12-19 F5 · shares: The reported transactions involved a transfer of an outstanding common stock warrant from Michael Siek to the reporting person. F5 · price: The reported transactions involved a transfer of an outstanding common stock warrant from Michael Siek to the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 2,633 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 13 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,633 Underlying: Common Stock · 2,633 shares Expires 2024-12-19 F5 · shares: The reported transactions involved a transfer of an outstanding common stock warrant from Michael Siek to the reporting person. F5 · price: The reported transactions involved a transfer of an outstanding common stock warrant from Michael Siek to the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 1,593 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 12 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,593 Underlying: Common Stock · 1,593 shares Expires 2024-12-19 F5 · shares: The reported transactions involved a transfer of an outstanding common stock warrant from Michael Siek to the reporting person. F5 · price: The reported transactions involved a transfer of an outstanding common stock warrant from Michael Siek to the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 807 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 11 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 807 shares Expires 2024-12-19 F4 · shares: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F4 · price: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | Disposition to issuerCommon Stock Warrant · Derivative | 1,525 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 10 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,525 shares Expires 2024-12-19 F4 · shares: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F4 · price: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 36,900 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 9 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,900 Underlying: Common Stock · 36,900 shares Expires 2024-12-19 F3 · shares: The two reported transactions involved an amendment of an outstanding pursuant to a transfer of a portion of the Warrant with Michael Siek common stock warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F3 · price: The two reported transactions involved an amendment of an outstanding pursuant to a transfer of a portion of the Warrant with Michael Siek common stock warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | Disposition to issuerCommon Stock Warrant · Derivative | 10,086 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 8 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,086 shares Expires 2024-12-19 F3 · shares: The two reported transactions involved an amendment of an outstanding pursuant to a transfer of a portion of the Warrant with Michael Siek common stock warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F3 · price: The two reported transactions involved an amendment of an outstanding pursuant to a transfer of a portion of the Warrant with Michael Siek common stock warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 22,108 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 7 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,108 Underlying: Common Stock · 22,108 shares Expires 2024-12-19 F2 · shares: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F2 · price: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | Disposition to issuerCommon Stock Warrant · Derivative | 25,676 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 6 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,676 shares Expires 2024-12-19 F2 · shares: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F2 · price: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of the Warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.